About FDA
Office of Counterterrorism and Emerging Threats
The Office of Counterterrorism and Emerging Threats (OCET) mission is to facilitate the development and availability of safe and effective public health emergency medical countermeasures and establish policies to safeguard medical products from adulteration and prevent disruption of supplies as a result of terrorist activities.
Major Functions
Coordinates the portfolio of FDA counterterrorism and pandemic influenza policy and planning initiatives and serves as FDA’s point of entry on policy and planning matters concerning counter-terrorism and emerging threats
Coordinates FDA’s Medical Countermeasures Initiative (MCMi)
Develops and implements strategies to identify and address gaps in efforts to protect medical products from adulteration and to prevent terrorists from disrupting supplies
Develops and coordinates implementation of FDA policies to make sure safe and effective medical products are available to counter chemical, biological, radiological, and nuclear (CBRN) agents of concern
Leads FDA's emergency use authorization (EUA) activities regarding public health emergencies, including emerging threats and terrorism
Collaborates closely with FDA Centers and Offices and with external partners to develop and coordinate implementation of pandemic influenza preparedness plans and programs to counter other emerging threats
Facilitates, on behalf of the Office of the Commissioner, intra- and inter-agency communications on counterterrorism policy and pandemic influenza preparedness
Contact FDA
Dr. Luciana Borio
Assistant Commissioner for Counterterrorism Policy and Director, Office of Counterterrorism and Emerging Threats